Sutro Biopharma (STRO) Total Debt (2017 - 2023)

Sutro Biopharma has disclosed Total Debt across 7 years of filings, most recently posting $4.1 million for Q4 2023.

• Total Debt for Q4 2023 came in at $4.1 million, down 75.04% year-over-year; the trailing twelve-month figure through Dec 2023 was $4.1 million (down 75.04% YoY), and the FY2023 annual result was $4.1 million, down 75.04% from the prior year.
• Total Debt came in at $4.1 million for Q4 2023 at Sutro Biopharma, down from $7.1 million in the prior quarter.
• In the past five years, Total Debt ranged from a high of $25.3 million in Q1 2022 to a low of $4.1 million in Q4 2023.
• The 5-year median for Total Debt is $20.8 million (2022), against an average of $18.1 million.
• Across the five-year window, Total Debt jumped 148.53% in 2020 and slumped 75.04% in 2023, its largest moves.
• Sutro Biopharma's Total Debt stood at $9.9 million in 2019, then surged by 148.53% to $24.5 million in 2020, then gained by 2.31% to $25.1 million in 2021, then plunged by 35.21% to $16.3 million in 2022, then plunged by 75.04% to $4.1 million in 2023.
• The last three Total Debt figures came in at $4.1 million (Q4 2023), $7.1 million (Q3 2023), and $10.2 million (Q2 2023), per Business Quant data.